U.S. markets open in 8 hours 46 minutes
  • S&P Futures

    4,389.00
    -4.75 (-0.11%)
     
  • Dow Futures

    34,844.00
    +10.00 (+0.03%)
     
  • Nasdaq Futures

    14,971.00
    -40.50 (-0.27%)
     
  • Russell 2000 Futures

    2,225.10
    +4.40 (+0.20%)
     
  • Crude Oil

    72.65
    +0.26 (+0.36%)
     
  • Gold

    1,814.50
    +14.80 (+0.82%)
     
  • Silver

    25.26
    +0.39 (+1.56%)
     
  • EUR/USD

    1.1864
    +0.0017 (+0.14%)
     
  • 10-Yr Bond

    1.2610
    -1.2610 (-100.00%)
     
  • Vix

    18.31
    -19.36 (-100.00%)
     
  • GBP/USD

    1.3923
    +0.0015 (+0.10%)
     
  • USD/JPY

    109.7880
    -0.1220 (-0.11%)
     
  • BTC-USD

    40,107.35
    +377.12 (+0.95%)
     
  • CMC Crypto 200

    938.45
    +8.52 (+0.92%)
     
  • FTSE 100

    7,016.63
    +20.55 (+0.29%)
     
  • Nikkei 225

    27,789.16
    +207.50 (+0.75%)
     

Is Inovio Pharmaceuticals Primed For a Comeback?

·4 min read
Is Inovio Pharmaceuticals Primed For a Comeback?

It seems like a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered a leader in the race to develop an effective coronavirus vaccine. Unsurprisingly, investors mostly gave up on Inovio, and its shares have lost more than half their value in the past 12 months. Inovio hasn't given up on its COVID-19 vaccine program, but the biotech can't conduct a phase 3 clinical trial for INO-4800 in the U.S. at the moment.